Reuters Pfizer dropped as much as 6% on Tuesday after Wall Street analysts knocked its recent deal with Mylan. Pfizer’s off-patent drug business Upjohn will merge with Mylan by the end of 2020. Morgan Stanley and Bank of America Merrill Lynch both downgraded the stock from "buy" to "neutral," citing profitability concerns. UBS said it […]